Home › Funds › ESSEX INVESTMENT MANAGEMENT CO LLC › XERS
ESSEX INVESTMENT MANAGEMENT CO LLC position in XERS
Xeris Biopharma Holdings Inc · Health Care
ESSEX INVESTMENT MANAGEMENT CO LLC reported holding 693,260 shares of XERS (Xeris Biopharma Holdings Inc) in its Q3 2026 13F filing — a position valued at US$6.6M, representing 0.99% of its reported portfolio and ranking #23 among its reported holdings. ESSEX INVESTMENT MANAGEMENT CO LLC has disclosed XERS holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-10-21 · Source: SEC EDGAR Form 13F-HR
How ESSEX INVESTMENT MANAGEMENT CO LLC's XERS position evolved
ESSEX INVESTMENT MANAGEMENT CO LLC first disclosed a stake in XERS in Q4 2024 at 474,955 shares (US$1.6M). The position peaked in Q3 2026 at 693,260 shares, worth US$6.6M. Across 8 filings, ESSEX INVESTMENT MANAGEMENT CO LLC increased the stake 3 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 693,260 shares valued at US$6.6M — a reduction of -22,348 shares quarter over quarter.. Notable position changes include a 54% increase in Q1 2025 (shares fell 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 474.95K | $1.61M | New |
| Q1 2025 | 730.44K | $4.01M | Add |
| Q2 2025 | 725.77K | $3.39M | Reduce |
| Q3 2025 | 750.03K | $6.11M | Add |
| Q4 2025 | 734.53K | $5.77M | Reduce |
| Q1 2026 | 747.77K | $4.34M | Add |
| Q2 2026 | 715.61K | $5.67M | Reduce |
| Q3 2026 | 693.26K | $6.63M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XERS and 13F data
XERS (Xeris Biopharma Holdings Inc) is a Health Care company. 52 other funds we track also report a position in XERS — the largest reported positions include CAPSTONE INVESTMENT ADVISORS, LLC (US$62.6M), Polar Asset Management Partners Inc. (US$28.8M), Rosalind Advisors, Inc. (US$23.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XERS
- CAPSTONE INVESTMENT ADVISORS, LLC 23.07M sh · $62.64M · Q2 2026
- Polar Asset Management Partners Inc. 10.50M sh · $28.80M · Q2 2026
- Rosalind Advisors, Inc. 2.91M sh · $23.04M · Q2 2026
- Parkman Healthcare Partners LLC 1.81M sh · $14.32M · Q2 2026
- Vilga Financial Planning LLC 1.06M sh · $10.13M · Q3 2026
- Ishara Investments LP 1.23M sh · $9.74M · Q2 2026
- Knott David M Jr 1.06M sh · $8.40M · Q2 2026
More on ESSEX INVESTMENT MANAGEMENT CO LLC
FAQ
How long has ESSEX INVESTMENT MANAGEMENT CO LLC held XERS?
ESSEX INVESTMENT MANAGEMENT CO LLC has disclosed XERS holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is ESSEX INVESTMENT MANAGEMENT CO LLC's current position in XERS?
As of Q3 2026, ESSEX INVESTMENT MANAGEMENT CO LLC holds 693.26K shares of XERS (Xeris Biopharma Holdings Inc), valued at $6.63M, representing 0.99% of its reported portfolio and ranking #23.
Has ESSEX INVESTMENT MANAGEMENT CO LLC been buying or selling XERS?
In the latest 13F filing (Q3 2026), ESSEX INVESTMENT MANAGEMENT CO LLC reduced its position in XERS. The position peaked in Q3 2026 at 693.26K shares.
Which other funds hold XERS?
Other major institutional holders of XERS include CAPSTONE INVESTMENT ADVISORS, LLC, Polar Asset Management Partners Inc., Rosalind Advisors, Inc., among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.